About Authors:
Vaibhav Patel*, Punit Bhatnagar, Gopal Rai, Alok Pal Jain
Guru Ramdas Khalsa Institute of Science & Technology (Pharmacy),

Gene therapy by small interfering RNAs (siRNAs) hasbeen emerging as innovative nucleic acid medicines with increasing knowledge on the molecular mechanisms of endogenous RNA interference. Gene silencingis a promising tool for the treatment of numerous human diseases that cannot be cured by rational therapies. The primary success of siRNA applications depends on suitable vectors to deliver therapeutic genes.

Reference Id: PHARMATUTOR-ART-1386

Historical Aspect
siRNA was first discovered by David Baulcombe’s group at the Sainsbury laboratory in Norwich, England as a part of post-transcriptional gene silencing (PTGS) in plants. This innovative output was first published in a paper entitled as “A species of small antisense RNA in post-transcriptional gene silencing in plants” in October 1999. In the same sequence various studies has been continuously carried out to explore the therapeutic potential of siRNA to its utmost extent.

siRNAalso known as short interfering RNA or silencing RNA. It is a class of double-stranded RNA molecules of 20-25 nucleotides in length having a 5' phosphate group and a 3' hydroxyl (OH) group, with 3' overhangs (2 nucleotides) at each end that can be used to "interfere" with the translation of proteins. They specifically bind to a particular sequence of gene on mRNA and thus by promoting the degradation of specific proteins they act as a biotechnology tool to treat diseases like cancer etc. In this way, they prevent the production of specific proteins based on the nucleotide sequences of their corresponding mRNA. The process is called RNA interference (RNAi), and may also be referred to as “siRNA silencing or siRNA knockdown”. si-RNA is generally considered to have come from longer strands of exogenous RNA which is taken up by the cell and undergoes further processing.

The siRNA can be successfully delivered by novel drug delivery tools like nanoparticles, liposomes, micelles, vectors, viruses or transposons etc. Once they entered the cell they are acted upon by RNase III–like enzyme, called Dicer, using restriction enzymes. The si-RNA is then incorporated into a multi-subunit protein complex called RNAi induced silencing complex (RISC). RISC "seeks out" an appropriate target mRNA. In the same sequence it was hypothesized by some researchers that; it acts as an antisense strand which directs the degradation of the complimentary strand of mRNA, by using a combination of endo- and exonuclease enzymes. siRNA have been found to play a crucial role in antiviral defense, degradation of over-produced mRNA, in shaping the chromatin structure of a genome or preventing disruption of genomic DNA by transposons. Many diseases can potentially be treated by inhibiting gene expression due to which siRNA has drawn a major attention of various academic researchers and biopharmaceutical companies.

Design for synthetic siRNA
Recently numbers of designs for the manufacturing of siRNA has been put forward by scientists and along with that they are continuously trying to espy some alternate protective drug delivery route for safe and effective delivery of siRNA.    

General Guidelines for the Design of siRNA

  1. siRNA targeted sequence is usually 21 nucleotide in length.
  2. Avoid regions within 50-100 bp of the start codon and the termination codon.
  3. Avoid intron regions.
  4. Avoid stretches of 4 or more bases such as AAAA, CCCC.
  5. Avoid regions with GC content <30% or > 60%.
  6. Avoid repeats and low complex sequence.
  7. Avoid single nucleotide polymorphism (SNP) sites.
  8. Perform BLAST homology search to avoid off-target effects on other genes or sequences.
  9. Always design negative controls by scrambling targeted siRNA sequence.

A delineative architecture of a typical hairpin siRNA developed by a siRNA expression vector is described in the given Figure 1.

Figure 1.Schematic representation of a typical hairpin siRNA produced by a siRNA expression vector

Synthesis of siRNA
Recommendations for siRNA hairpin design and cloning strategy are made based on research by Ambion scientist's procedures. The first step in designing an appropriate insert is to choose the siRNA target site which is done by scanning an mRNA sequence for AA dinucleotides and recording the 19 nucleotides immediately downstream of the AA. After that a siRNA expression cassette is constructed  in a specific order of sense strand, short spacer and antisense strand. The length of the siRNA stem should range between 19 to 22 nucleotides-long sequences and the loop size should lie between 3 to 23 nucleotides. Various scientific studies have revealed that these specific stem lengths and loop sizes functions well in gene silencing studies.



Subscribe to PharmaTutor Alerts by Email